MNA – Iranian biotech medicines exported to Russia have taken over the country’s market 100% and have replaced their American versions, according to National Talents Foundation.


Meanwhile, Iran’s status in the field of knowledge-based and innovative economy has leaped 42 places in global indexes in 2016 and reached 78th place from 120th in 2014.

Drug registration requires performing clinical trials. The Iranian biotech medicines have undergone clinical trials for three years until they obtained approvals from Russia.

For the first time, two Iranian bio drugs are undergoing registration process in Europe. Meanwhile, five Iranian bio medicines have already been registered in Russia and completely replaced their American versions in the Russian market.

One of the exported medicines to Russia is a drug used in treatment of Multiple sclerosis (MS). The anti-cancer drug has recently received approval and is being currently exported. Furthermore, the export of Iranian medicines to Iraq and Turkey has gone underway following the same process.